Gyre Therapeutics (GYRE) Accounts Payables (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Accounts Payables of $265000.0 for Q1 2026, up 117.21% year-over-year from $122000.0 in Q1 2025, and up 113.71% quarter-over-quarter from $124000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Accounts Payables (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Accounts Payables for 17 consecutive years, with $265000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 117.21% year-over-year to $265000.0; the TTM figure through Mar 2026 stood at $265000.0 (up 117.21% YoY), while the FY2025 annual figure was $124000.0, up 14.81% from the prior year.
- Accounts Payables climbed to $265000.0 in Q1 2026 per GYRE's latest filing, from $124000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $4.7 million in Q1 2022 and bottomed at $5000.0 in Q2 2023.
- Historically, Accounts Payables has averaged $505294.1 across 5 years, with a median of $158000.0 in 2023.
- Annual changes were most pronounced in 2023 — Accounts Payables plunged 99.66% — and 2024, when it surged 5320.0%.
- Gyre Therapeutics' Accounts Payables stood at $122000.0 in 2022, then soared by 190.98% to $355000.0 in 2023, then sank by 69.58% to $108000.0 in 2024, then advanced by 14.81% to $124000.0 in 2025, then soared by 113.71% to $265000.0 in 2026.
- Business Quant data shows GYRE's Accounts Payables at $265000.0 in Q1 2026, $124000.0 in Q4 2025, and $556000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.24 Mn |
| Mar 31, 2026 | 265,000.00 |
| Dec 31, 2025 | 124,000.00 |
| Sep 30, 2025 | 556,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Dec 31, 2024 | 108,000.00 |
| Sep 30, 2024 | 303,000.00 |
| Jun 30, 2024 | 271,000.00 |
| Mar 31, 2024 | 330,000.00 |
| Dec 31, 2023 | 355,000.00 |
| Sep 30, 2023 | 158,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | 16,000.00 |
| Dec 31, 2022 | 122,000.00 |
| Sep 30, 2022 | 41,000.00 |
| Jun 30, 2022 | 1.04 Mn |
| Mar 31, 2022 | 4.71 Mn |
| Dec 31, 2021 | 6.42 Mn |
| Sep 30, 2021 | 3.86 Mn |